Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

398.25USD
3:39pm EDT
Change (% chg)

$3.35 (+0.85%)
Prev Close
$394.90
Open
$393.00
Day's High
$398.49
Day's Low
$391.13
Volume
133,541
Avg. Vol
271,221
52-wk High
$605.83
52-wk Low
$329.22

REGN.OQ

Chart for REGN.OQ

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the... (more)

Overall

Beta: 1.05
Market Cap(Mil.): $41,495.54
Shares Outstanding(Mil.): 105.08
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 62.72 41.28 37.71
EPS (TTM): 6.30 -- --
ROI: 16.79 -9.20 14.43
ROE: 21.55 -9.24 15.61

BRIEF-Regeneron and Sanofi announce approval of praluent (alirocumab) in Japan

* Regeneron and Sanofi announce approval of praluent (alirocumab) for the treatment of hypercholesterolemia in Japan Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 05 2016

Sanofi and Regeneron report positive skin disease trial

PARIS French drugmaker Sanofi SA and U.S. partner Regeneron Pharmaceuticals Inc said a one-year, late-stage study of dupilumab, a monoclonal antibody designed for the treatment of skin diseases, had met its main goals.

Jun 06 2016

Sanofi and Regeneron report positive skin disease trial

PARIS, June 6 French drugmaker Sanofi SA and U.S. partner Regeneron Pharmaceuticals Inc said a one-year, late-stage study of dupilumab, a monoclonal antibody designed for the treatment of skin diseases, had met its main goals.

Jun 06 2016

BRIEF-Regeneron presents positive data from phase 2 study of Evinacumab

* Regeneron presents positive interim data from phase 2 proof-of-concept study of Evinacumab in patients with homozygous familial hypercholesterolemia

May 31 2016

Biotech Regeneron replaces Intel as sponsor of Science Talent Search

NEW YORK Biotechnology company Regeneron Pharmaceuticals Inc on Thursday became the title sponsor of the most prestigious U.S. science competition for high school students, taking the baton from chipmaker Intel Corp.

May 26 2016

RPT-Biotech Regeneron replaces Intel as sponsor of Science Talent Search

NEW YORK, May 25 Biotechnology company Regeneron Pharmaceuticals Inc on Thursday became the title sponsor of the most prestigious U.S. science competition for high school students, taking the baton from chipmaker Intel Corp .

May 26 2016

Biotech Regeneron replaces Intel as sponsor of Science Talent Search

NEW YORK, May 26 Biotechnology company Regeneron Pharmaceuticals Inc on Thursday became the title sponsor of the most prestigious U.S. science competition for high school students, taking the baton from chipmaker Intel Corp .

May 26 2016

Pfizer's Anacor deal showcases new wave of eczema therapies

NEW YORK Pfizer Inc's purchase of Anacor Pharmaceuticals Inc heralds an approaching wave of potentially safer and more effective treatments for millions who suffer from eczema, a common skin condition which causes infection-prone rashes that can feel like having poison ivy 24 hours a day.

May 17 2016

BRIEF-Temasek Holdings ups share stake in Regeneron Pharma as of March 31

May 16 Temasek Holdings Raises Share Stake In Regeneron Pharmaceuticals To 126,351 Shares From 58,289 Shares - SEC filing

May 16 2016

Regeneron CEO says drug price critique by independent group unscientific

NEW YORK Regeneron Pharmaceuticals Chief Executive Leonard Schleifer on Thursday took aim at an influential drug pricing watchdog, saying a critique of the company's new cholesterol lowering therapy was non-scientific.

May 12 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF82.50 +0.30
Pfizer Inc. (PFE.N) $36.76 -0.02
Bayer AG (BAYGn.DE) €93.57 +0.95
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.57 +0.06
Merck & Co., Inc. (MRK.N) $58.29 -0.27
Amgen, Inc. (AMGN.OQ) $167.60 +1.04
Roche Holding Ltd. (ROG.S) CHF250.30 +1.50
Roche Holding Ltd. (RO.S) CHF251.25 +1.25
Eli Lilly and Co (LLY.N) $81.98 0.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.